2026-07-01 11:52:57 am | Source: PR Agency
Morepen starts commercial supplies under its Rs 825 Crore CDMO mandate
Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) today issued an update on its recently announced ?825 crore CDMO mandate. The first commercial dispatch, valued at approximately ?50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage.
Commenting on the development, Mr. Sanjay Suri, Managing Director, Morepen Laboratories Limited, said, “This is an important milestone in Morepen’s transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities.”
Having dispatched the first batch under the CDMO mandate, Morepen expects to scale the program further in the coming quarter, with additional supplies of approximately ?225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements.
The Company continues to strengthen its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases.
The commencement of commercial supplies under this mandate reinforces Morepen’s strategy to build a scalable CDMO platform, deepen customer partnerships and participate in long-duration global manufacturing opportunities.
Above views are of the author and not of the website kindly read disclaimer
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
Buy Atul Ltd For Target Rs.7,100 by Motilal Oswal Fi...
Buy Godrej Properties Ltd For Target Rs.2,200 by Mot...
Buy Jindal Stainless Ltd For Target Rs.910 by Motila...
Neutral Dr Reddy's Labs Ltd For Target Rs.1,180 by M...
Neutral Torrent Pharma Ltd For Target Rs.4,970 by Mo...
Buy Shriram Finance Ltd For Target Rs.1,155 by Motil...
Buy JSW Steel Ltd For Target Rs.1,470 by Motilal Os...
Automobiles Sector Report :Strong pre-festive season...
Upgrade to Buy BSE Ltd For Target Rs.4,000 by Motila...
Buy Adani Ports & SEZ Ltd For Target Rs.2,130 by Mot...
